Our aim is to open within 30 sites in the UK. PANTHER is not yet open to recruitment, however if you would be interested in joining, please select the contact button and drop us an email. OpenClinica will be used for randomisation and Florence will be the eISF.
To access the study documents for the trial – please select the resources tab.
PANTHER aims to accelerate the development of pharmacological therapies for patients with acute respiratory distress syndrome (ARDS) by establishing an international phase 2 precision medicine adaptive platform trial to test the efficacy of prioritised pharmacological interventions in patients with ARDS with different subphenotypes. In the event of a new pandemic, the trial will include these patients.
We have identified two subphenotypes in patients with ARDS: hypoinflammatory and hyperinflammatory. Patients from each subphenotype may respond differently to some treatments. PANTHER aims to identify which patient subphenotype will respond best to a treatment to improve patient care.
The adaptive nature of the trial means interventions can be removed and added to the study.
These interventions are currently all being compared usual care.
The current interventions in the trial include
Simvastatin
Baricitinib
Usual Care
18th of July 2025 11:00 – 12:00
Study Launch
Study launch webinar with Prof Danny McAuley
upcoming event – more details coming soon
upcoming event – more details coming soon
Ignited by Incendiary